Patents Issued in June 21, 2018
  • LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLAMMATION MEDIATED CONDITIONS
    Publication number: 20180169091
    Abstract: The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Inventor: Bruce Chandler May
  • PHARMACEUTICAL FORMULATIONS FOR TREATING GLAUCOMA AND METHODS FOR FABRICATING AND USING THEREOF
    Publication number: 20180169092
    Abstract: Pharmaceutical compositions for treating or mitigating glaucoma are described, the compositions comprising several separate components for an improved effect. Methods for fabricating the compositions and using them are also described.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 21, 2018
    Inventors: Dennis Elias Saadeh, Mark L. Baum
  • USE OF A STATIN COMPOUND AS LOCAL DRUG FOR TREATING OBESITY, DIABETES, HYPERTENSION AND HYPERLIPEMIA
    Publication number: 20180169093
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 21, 2018
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Yu
  • PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS
    Publication number: 20180169094
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Application
    Filed: January 9, 2015
    Publication date: June 21, 2018
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES
  • THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC)
    Publication number: 20180169095
    Abstract: Use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and healing of Digital Ulcers which are concomitant to fibrotic diseases, such as systemic sclerosis and scleroderma.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 21, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Claudia HIRTH-DIETRICH, Peter SANDNER, Johannes-Peter STASCH, Michael HAHN, Markus FOLLMANN, Alexandros VAKALOPOULOS
  • HETEROCYCLIC COMPOUNDS FOR TREATING PSORIASIS
    Publication number: 20180169096
    Abstract: Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: June 3, 2015
    Publication date: June 21, 2018
    Applicant: JS INNOPHARM (SHANGHAI) LTD.
    Inventors: Jintao ZHANG, Quanhai LIU, Minyu LIU, Xiaoling HUANG, Yifang DENG, Pengxia YU
  • COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
    Publication number: 20180169097
    Abstract: The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Kwok-kin Wong, Nathanael S. Gray
  • SMALL MOLECULES TARGETING HIV-1 NEF
    Publication number: 20180169098
    Abstract: A method of treating HIV in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a general Formula 1, or a pharmaceutically acceptable salt or ester thereof: wherein R1 is selected from H, optionally-substituted aryl, optionally-substituted heteroaryl, or optionally-substituted aliphatic; each R2 is independently selected from H, halogen, cyano, thioether, oxo, optionally-substituted amino, optionally-substituted heteroaryl, optionally-substituted aryl, or optionally-substituted aliphatic; a is 3 to 7; and the ring designates a heterocyclic or heteroaryl structure.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventor: Thomas E. Smithgall
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20180169099
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 21, 2018
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • Cancer Stem Cell Targeting Compounds
    Publication number: 20180169100
    Abstract: The present invention provides compounds of formula (I), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Included within the scope of such compounds, compositions, uses thereof and methods are those in which proliferation of cancer stem cells are selectively eradicated or inhibited.
    Type: Application
    Filed: March 11, 2015
    Publication date: June 21, 2018
    Inventors: Sangeeta Srivastava, Maithili Athavale, Kedar Shukre, Gayatri More
  • METHODS FOR TREATING CANCER
    Publication number: 20180169101
    Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.
    Type: Application
    Filed: October 26, 2017
    Publication date: June 21, 2018
    Inventor: Gary HATTERSLEY
  • Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition
    Publication number: 20180169102
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Application
    Filed: February 14, 2018
    Publication date: June 21, 2018
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Sungho Han
  • METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS
    Publication number: 20180169103
    Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
    Type: Application
    Filed: February 2, 2018
    Publication date: June 21, 2018
    Inventors: James L. Yeager, David J. Goldberg, Stephen M. Paridon
  • FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20180169104
    Abstract: Disclosed are methods for treating various bacterial infections with (2R,4S,4aS)-11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2?H,6H-spiro[1,4-oxazino[4,3-a][1,2]oxazolo[4,5-g]quinoline-5,5?-pyrimidine]-2?,4?,6?(1?H,3?H)-trione, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2015
    Publication date: June 21, 2018
    Inventor: Michael Huband
  • TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS
    Publication number: 20180169105
    Abstract: The present invention relates to interferon-gamma (IFN-?) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-? production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Inventors: Laurence HARBIGE, Michael LEACH
  • CEFTOLOZANE-TAZOBACTAM PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180169106
    Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joseph TERRACCIANO, Nicole Miller DAMOUR, Chun JIANG, Giovanni FOGLIATO, Giuseppe Alessandro DONADELLI, DARIO RESEMINI
  • METHODS FOR TREATING HYPERSOMNIA
    Publication number: 20180169107
    Abstract: Provided herein are methods, formulations and dosing regimens for treating hypersomnia in a subject. For instance, methods provided herein comprise administering a GABAA chloride channel blocker. In certain embodiments, the GABAA chloride channel blocker is pentylenetetrazol (PTZ).
    Type: Application
    Filed: April 14, 2015
    Publication date: June 21, 2018
    Inventor: Lyndon LIEN
  • Drug Combinations For the Treatment of HIV
    Publication number: 20180169108
    Abstract: Provided herein are effective latency-reversing agent (LRA) combinations of drugs for the reversal of HIV-1 latency. Such methods utilize, for example, the combination of a protein kinase C agonist and a bromodomain inhibitor combine to reverse latency or a NF?B activator combined with histone deacetylase inhibitors to reverse latency. These findings are surprising considering that many of the individual drug in these combinations show no effect alone. Novel drug combinations for reversal of HIV-1 latency/reactivation of latent HIV-1 may include 1) disulfiram (acetaldehyde dehydrogenase inhibitor, activator of NF-?B via AKT signaling) plus histone deacetylase inhibitors or 2) protein kinase C agonists with bromodomain inhibitor JQ1. Latency-reversing drug combinations for use in HIV-1 infected individuals may eliminate the HIV-1 reservoir for cure/long-term drug-free remission.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 21, 2018
    Inventors: Gregory M. LAIRD, Robert SILICIANO, Cynthia K. BULLEN
  • TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES
    Publication number: 20180169109
    Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 21, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
  • Nrf2 REGULATORS
    Publication number: 20180169110
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Inventors: Jeffrey K. KERNS, Jamas Francis CALLAHAN, Hongxing YAN, Thomas Daniel HEIGHTMAN, Jeffrey Charles BOEHM, Alison Jo-Anne WOOLFORD
  • METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT
    Publication number: 20180169111
    Abstract: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use.
    Type: Application
    Filed: November 17, 2017
    Publication date: June 21, 2018
    Applicant: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • PHARMACEUTICAL USE
    Publication number: 20180169112
    Abstract: The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and ?-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and ?-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.
    Type: Application
    Filed: December 18, 2017
    Publication date: June 21, 2018
    Inventor: Alfred Schmidt
  • HIGH CONCENTRATION FORMULATION
    Publication number: 20180169113
    Abstract: The present disclosure provides high concentration formulations of cortexolone-17?-propionate suitable for treating alopecia.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 21, 2018
    Applicant: Cassiopea S.P.A.
    Inventor: Luigi Maria LONGO
  • METHODS FOR REDUCING CELLULAR PROLIFERATION AND TREATING CERTAIN DISEASES
    Publication number: 20180169114
    Abstract: Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Paul B. Savage
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
    Publication number: 20180169115
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • TREATMENT OF OTITIS MEDIA WITH RETROAURICULAR INJECTION OF AN ANTI-INFLAMMATORY DRUG
    Publication number: 20180169116
    Abstract: The present invention relates to the treatment of otitis media, in particularly secretory otitis media, with an anti-inflammatory drug such as a steroid or a non-steroid anti-inflammatory drug, wherein said anti-inflammatory drug is formulated as a depot formulation for retroauricular injection.
    Type: Application
    Filed: June 30, 2016
    Publication date: June 21, 2018
    Inventor: Michael Lyhne Gaihede
  • PHARMACEUTICAL FORMULATION COMPRISING A SUBSTITUTED PHENYL - (1,3-DIHYDRO-ISOINDOL-2-YL) - METHANONE
    Publication number: 20180169117
    Abstract: Provided herein are formulations of (2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone of formula (I): or a L-lactate salt thereof, in a phosphate or succinate buffer.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 21, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: David Alexander RAWLINS, Sanjeev REDKAR, Rajashree JOSHI-HANGAL
  • NOVEL PRODRUG SALTS
    Publication number: 20180169118
    Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.
    Type: Application
    Filed: October 24, 2017
    Publication date: June 21, 2018
    Applicant: AEROMICS, INC.
    Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE
  • COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN
    Publication number: 20180169119
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid form or a salt form, such as a disodium salt form, can be used to treat or alleviate pain or related conditions, such as low back pain.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Inventor: Herriot Tabuteau
  • COMBINATION THERAPY INCLUDING SAPC-DOPS FOR THE TREATMENT OF PANCREATIC CANCER
    Publication number: 20180169120
    Abstract: Disclosed herein, according to the present invention, are methods of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising Saposin C and dioleoylphosphatidylserine (SapC-DOPS) and administering a second pharmaceutical composition comprising an anti-neoplastic agent. Optionally, additional pharmaceutical compositions may be administered. Also disclosed are methods of inhibiting tumor growth. Also disclosed are kits for the treatment of pancreatic cancer comprising at least two pharmaceutical compositions, wherein a first pharmaceutical composition comprises SapC-DOPS and wherein a second pharmaceutical composition comprises a first antineoplastic agent.
    Type: Application
    Filed: November 21, 2017
    Publication date: June 21, 2018
    Inventors: Xiaoyang Qi, Olugbenga Olowokure, Ray Takigiku
  • NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF
    Publication number: 20180169121
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 21, 2018
    Applicant: ABBOTT LABORATORIES
    Inventors: Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
  • SYNTHETIC COMPOSITION AND METHOD FOR TREATING IRRITABLE BOWEL SYNDROME
    Publication number: 20180169122
    Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2?-fucosyllactose (2?-FL) and lacto-N-neotetraose (LNnT).
    Type: Application
    Filed: February 14, 2018
    Publication date: June 21, 2018
    Inventors: Thierry Hennet, Bruce McConnell, Emma Salomonsson, Louise Kristine Vigsnæs
  • COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE
    Publication number: 20180169123
    Abstract: The present invention relates to a combined preparation comprising 2-deoxyglucose and a flavagline and to the use of said combined preparation as a medicament or in the treatment of cancer. Moreover, the present invention relates to a flavagline for use in a combination therapy against cancer comprising administration of 2-deoxyglucose; and to 2-deoxyglucose for use in a combination therapy against cancer comprising administration of a flavagline. Also, the present invention relates to methods for treating cancer and to processes for the preparation of a combined preparation according to the invention.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 21, 2018
    Inventors: Magnus VON KNEBEL DOEBERITZ, Matthias KLOOR, Aysel AHADOVA, Juergen KOPITZ, Peter KRAMMER, Min LI-WEBER
  • SUSTAINED RELEASE OF ANTIINFECTIVES
    Publication number: 20180169124
    Abstract: Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 21, 2018
    Inventors: Lawrence T. BONI, Brian S. MILLER
  • COMPOSITIONS OF MULTICATIONIC DRUGS FOR REDUCING INTERACTIONS WITH POLYANIONIC BIOMOLECULES AND METHODS OF USE THEREOF
    Publication number: 20180169125
    Abstract: The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 21, 2018
    Inventor: Vladimir Malinin
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180169126
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 21, 2018
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • COMPOSITIONS AND METHODS THAT MODULATE WHITE BLOOD CELLS OR NEUTROPHILS IN A COMPANION ANIMAL
    Publication number: 20180169127
    Abstract: White blood cells and/or neutrophils in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the white blood cells and/or neutrophils.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 21, 2018
    Inventors: Rondo P. Middleton, Brian M. Zanghi, Serge Andre Dominique Rezzi, Steven S. Hannah
  • IMMUNOASSAY OF S-ADENOSYLMETHIONINE USING ANALOGS THEREOF AND PERSONALIZED THERAPEUTICS
    Publication number: 20180169128
    Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 21, 2018
    Inventors: Xiujuan Hao, Isaac Angres
  • POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
    Publication number: 20180169129
    Abstract: The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting an angiotensinogen (AGT) gene, and methods of using such polynucleotide agents to inhibit expression of AGT and to treat subjects having an AGT-associated disease, e.g., hypertension.
    Type: Application
    Filed: May 25, 2016
    Publication date: June 21, 2018
    Inventor: Gregory Hinkle
  • COMBINED THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY
    Publication number: 20180169130
    Abstract: The present invention relates to the combined use of antisense oligonucleotides and viral vectors for the treatment of Duchenne muscular dystrophy.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Inventors: Stephanie LORAIN, Thomas VOIT, Matthew WOOD, Graham MCCLOREY
  • ALLELE SPECIFIC MODULATORS OF P23H RHODOPSIN
    Publication number: 20180169131
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 21, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan F. MURRAY, Punit P. SETH, Michael L. McCALEB, Susan M. FREIER, Priyam SINGH
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180169132
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 21, 2018
    Inventor: Anna Borodovsky
  • Pet Food Compositions
    Publication number: 20180169133
    Abstract: Described herein are pet food compositions comprising a blood glucose management component comprising soy isoflavone and yeast beta-glucan (?-glucan); along with methods of making and using same.
    Type: Application
    Filed: December 16, 2016
    Publication date: June 21, 2018
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Matthew Jackson, Dennis Jewell
  • CHITOSAN MATERIALS FROM CARBONIC ACID SOLUTION
    Publication number: 20180169134
    Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Inventors: Simon McCarthy, Barbara McGrath, Sam Kuhn, Jess Kimball, Michael Stolten, Amanda Bennett
  • METHOD FOR PREVENTING TRANSPLANT FAILURE IN A HOST
    Publication number: 20180169135
    Abstract: This invention is in the field of medical treatment, in particular the invention provides a method for the prevention, amelioration or reduction of transplant failure in a host organism. More in particular, the invention provides a pentasaccharide-depleted heparin for use in preventing, ameliorating or reducing transplant failure of a foreign organ or tissue of the human or animal body into a recipient.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Inventors: Lodewijk Willem Ernest Van Heurn, Gerardus Anna Franciscus Nicolaes, Christiaan Peter Maria Reutelingsperger, Tim Christian Van Smaalen
  • USE OF PHARMACEUTICAL COMPOSITION IN PREPARATION OF DRUG FOR PROMOTING CHONDROCYTE GENERATION
    Publication number: 20180169136
    Abstract: The present invention relates to a use of a pharmaceutical composition in the preparation of a drug for promoting chondrogenesis, wherein the pharmaceutical composition comprises a hyaluronic acid mixture and a statin compound.
    Type: Application
    Filed: June 18, 2015
    Publication date: June 21, 2018
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Mei-ling Ho, Je-Ken Chang, Shun-Cheng Wu, Chih-Hsiang Chang
  • COMPOSITIONS AND METHODS COMPRISING GROWTH FACTORS, CHONDROITIN AND GLUCOSAMINE FOR DEGENERATIVE DISC REGENERATION
    Publication number: 20180169137
    Abstract: There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.
    Type: Application
    Filed: November 4, 2016
    Publication date: June 21, 2018
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventor: William Mark ERWIN
  • Use Of Gastrointestinally Administered Porous Enteron Sorbent Polymers To Prevent Or Treat Radiation Induced Mucositis, Esophagitis, Enteritis, Colitis, And Gastrointestinal Acute Radiation Syndrome
    Publication number: 20180169138
    Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
    Type: Application
    Filed: February 2, 2018
    Publication date: June 21, 2018
    Inventors: Humayra Begum Ali, Thomas D. Golobish, Vincent J. Capponi, Phillip P. Chan, Wei Tai Young, Andrew Robert Scheirer
  • COMPOSITION AND METHODS FOR TREATMENT OF LOSS OF FLUIDS LEADING TO HYPOTENSION AND/OR HYPOVOLEMIA
    Publication number: 20180169139
    Abstract: The present invention is directed to a composition containing at least one salt, at least one natural or synthetic saccharide, and at least one natural or synthetic high molecular weight, non-ionic, hydrophilic polymer. When in a liquid form, the composition is ready for infusion or injection to patients that suffer from loss of fluids that causes reduced volume and/or pressure in the systemic circulation. The composition is also suitable for treatment of organ conditions where blood flow is impaired or insufficient, resulting in organ distress, including tissue loss. The invention also relates to use as a prophylaxis to prevent medical consequences of anticipated conditions where depleted circulatory fluids, low blood pressure, or impaired organ perfusion require correction.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 21, 2018
    Applicant: Cellphire, Inc.
    Inventors: Giora FEUERSTEIN, Glen Michael FITZPATRICK
  • ANTIBIOTIC COMPOSITIONS AND METHODS OF USE
    Publication number: 20180169140
    Abstract: The present disclosure describes compositions comprising ?-lactam antibiotics and branched poly-ethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against ?lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as ?-lactam antibiotics.
    Type: Application
    Filed: June 16, 2016
    Publication date: June 21, 2018
    Inventor: Charles V. Rice